Statins and endocrine resistance in breast cancer

Tara Hyder¹, Juan Luis Gomez Martí², Azadeh Nasrazadani³, Adam M. Brufsky³

¹University of Pittsburgh Physicians, Pittsburgh, PA 15213, USA.
²Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
³UPMC Hillman Cancer Center, Magee Women’s Hospital, Pittsburgh, PA 15213, USA.

Correspondence to: Prof. Adam M. Brufsky, UPMC Hillman Cancer Center, Magee Women’s Hospital, Suite 4628, 300 Halket Street, Pittsburgh, PA 15213, USA. E-mail: brufskyam@upmc.edu


Received: 7 Dec 2020  First Decision: 4 Jan 2021  Revised: 10 Jan 2021  Accepted: 15 Jan 2021  Available online: 19 Jun 2021

Abstract
Most breast cancers are hormone-receptor positive (HR⁺). However, more women eventually die from HR⁻ breast cancer than from either HER2⁺ or triple negative breast cancer. Endocrine therapies continue to be the mainstay of treatment. In 40% of these cases, recurrences in early-stage disease and progression in the metastatic setting are largely a function of the development of endocrine resistance. A multitude of mediators and pathways have been associated with endocrine resistance in breast cancer including the mevalonate pathway, which is integral to cholesterol biosynthesis. The mevalonate pathway and the downstream activation of associated cytoplasmic pathways including PI3K-AKT-mTOR and RAS-MEK-ERK have been known to affect cancer cell proliferation, cell survival, cell invasion, and metastasis. These are important mechanisms leading to the inevitable development of endocrine resistance in HR⁻ breast cancer. Statins are a class of drugs that inhibits HMG-CoA reductase, an enzyme in the mevalonate pathway that plays a central role in cholesterol production. In vitro and in vitro studies suggest that the role of statins in blocking the mevalonate pathway effectively disrupts downstream pathways involved in estrogen receptor expression and cellular processes such as cell survival, proliferation, stress, cell cycle, inhibition of apoptosis, and autophagy. Overcoming these key mechanisms heralds a role for statins in the prevention of endocrine resistance.

Keywords: Statin, HMGCR, endocrine resistance, autophagy, PI3K, mTOR
ENDOCRINE RESISTANCE IN BREAST CANCER

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death in women throughout the world\(^1\). Roughly two-thirds of breast cancer patients have a hormone-receptor positive (HR\(^+\)) disease for which endocrine therapy is the mainstay of treatment. Endocrine therapy agents function by suppressing the expression of estrogen, in many cases by antagonizing the estrogen receptor (ER). Selective ER modulators (SERMs) such as tamoxifen competitively bind ER, forming an inactive complex that blocks estrogen effect on breast tissue\(^2\). These drugs are demonstrated to be effective in both premenopausal and postmenopausal women, although are preferentially utilized in premenopausal women. Aromatase inhibitors (AIs) such as letrozole, anastrozole, and exemestane aim to reduce peripheral estrogen production through inhibition of aromatase, which facilitates its conversion. AIs are primarily used in postmenopausal women, although there is a role for them in conjunction with GnRH analogues in the premenopausal setting.

A major challenge in treating HR\(^+\) breast cancer lies in overcoming endocrine resistance, which occurs in approximately 40% of patients\(^3\). Primary endocrine resistance is defined as a relapse within 2 years of adjuvant endocrine treatment or disease progression during the first 6 months of first-line endocrine therapy for advanced or metastatic breast cancer (MBC)\(^4\). Secondary resistance is defined in early breast cancer as a relapse that occurs after at least two years of endocrine therapy and during or within the first year of completing adjuvant endocrine therapy. In advanced or MBC, secondary resistance is defined as disease progression after more than 6 months of endocrine therapy.

Multiple mechanisms of endocrine resistance have been identified including deregulation of the ER signaling pathway, alteration of apoptosis and cell cycle regulation, and the overdrive of pro-proliferative pathways\(^5\text{-}8\). One potential pathway implicated in the development of endocrine resistance includes the mevalonate pathway, which is involved in the synthesis of cholesterol and isoprenoids such as geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate. As a result of this process, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) catalyzes the production of mevalonate from 3-hydroxy-3-methyl-glutaryl-CoA. Notably, increased expression of HMGCR has been correlated with increased tumor aggression and poorer prognosis\(^9\). This has led to an increased and newfound interest in statins, a class of drugs known to inhibit HMGCR and classically utilized for the management of hyperlipidemia. Various studies using a range of tumor cell lines have demonstrated anti-angiogenic, anti-proliferative, and pro-apoptotic properties of statins\(^10,11\). More importantly, statin intake has been associated with a decrease in breast cancer recurrence\(^12,13\). Herein, we review literature supporting the role for statins in the prevention of endocrine resistance and breast cancer recurrence.

CHOLESTEROL BIOSYNTHESIS AND METABOLISM DRIVES TAMOXIFEN RESISTANCE

Transcriptomic analysis of tamoxifen-resistant cell lines have shown increased expression of genes involved in the cholesterol biosynthesis pathway [Figure 1]. Specifically, genes associated with sterol regulatory element-binding factor (SREBF) activation were found to be upregulated in tamoxifen-resistant T47D cells\(^14\). SREBF is a transcription factor and primary activator of the mevalonate pathway, thereby suggesting that transcriptional reprogramming of resistant cells may be occurring via mevalonate pathway intermediaries. A recent study showed that AI-resistant cells exhibited a higher degree of expression of small Rab GTPase family proteins. This upregulation was also reflected by a remarkable increase in exosome production, meaning that prolonged endocrine therapy may lead to resistance not only by increasing autophagosome formation but also by increased release of small extracellular vesicles. Proteomic analysis demonstrated a 2-fold increase in vesicle-mediated transport. Of these, RAB27B, RAB5, and RAB11 were found to be significantly upregulated\(^15\). The relevance of these small GTPases relies on their roles in tumor invasion and metastasis, which have previously been reported elsewhere\(^16\text{-}18\). RAB27B has been found to
promote G1 to S phase transition, proliferation, and invasion in vitro. In vitro, increased Rab27B expression promoted tumor invasion and lymph node metastasis in an orthotopic model, primarily via geranylgeranyl diphosphate \cite{16}. By in silico analysis, Rab5A is found to be associated with poor prognosis in HR+ breast cancer (HR = 1.3 (1.01-1.6), P = 0.037) in multivariate analysis among tumors with Rab5A expression > 75% percentile \cite{17}. Rab5A expression is also induced by hypoxia \cite{19}. Interestingly, the hypoxic marker, HIF-1α, is upregulated in letrozole-treated tumors \cite{20}. Lastly, Rab11 is involved in controlling cell surface expression of integrin β1, which triggers mechanotransduction signals within the extracellular matrix, allowing for metastatic cell seeding. Lipophilic statins impair Rab11b association and activity in the cell membrane, preventing breast cancer cells from adapting to the brain microenvironment and consequent seeding \cite{18}. Lastly, free cholesterol and lipid droplets have been noted to accumulate in lysosomes of T47D tamoxifen-resistant cells, reflecting impaired lipid metabolism due to deficiencies in membrane permeability \cite{14}.

Figure 1. Mechanisms of endocrine resistance in breast cancer. Tamoxifen resistance has been associated with increased expression of the transcription factor SREBF (A). SREBF activates the transcription of mevalonate pathway (MVP) genes, like HMGCR (B). Activation of the mevalonate pathway induces prenylation of small GTPases such as Rho, Ras, or Rab (C). Ras prenylation leads to phosphorylation of PI3K (D), which activates Akt and mTOR to phosphorylate the residue, Ser167, of the estrogen receptor (ERα), which decreases sensitivity to tamoxifen (E). This leads to continued Erα-derived transcription and phosphorylation of Rb, accelerating G1/S cell cycle transition (F). Ras phosphorylation also activates MEK (G), which activates ERK1/2. The latter is associated to a senescence-associated secretory phenotype (SASP) (H). Created with Biorender.com.

Aberrant mechanisms within the phosphoinositide 3-kinases (PI3K) pathway are additionally implicated in tamoxifen resistance. Ras prenylation leads to phosphorylation of PI3K. The PI3K pathway is the most frequently implicated pathway in breast cancer \cite{21}. Activation of PI3K results in the production of phosphatidylinositol 3,4,5-triphosphate (PIP3) and subsequent recruitment of AKT protein into the cell membrane. The activation of AKT and the subsequent intracellular cascade of phosphorylation of other proteins, including mammalian target of rapamycin (mTOR), is a potent driver of cell cycle progression and survival. Additionally, ER phosphorylation at Ser167 by AKT leads to ligand-independent activation of Erα, a potent mechanism in the estrogen-independent growth of breast cancer cells \cite{22}. Multiple studies have demonstrated how the overactivation of the PI3K/AKT/mTOR pathway causes resistance to endocrine
treatments such as tamoxifen and aromatase inhibitors. In one study, MCF-7 cells were infected with a retrovirus encoding a constitutively active AKT gene, ΔAkt-1(CA)\[^{[23]}\]. The effects of the hormonal drug, 4-hydroxytamoxifen (4HT), were compared between the ER+ MCF-7 and MCF7/ΔAkt-1(CA). It was found that the MCF7/ΔAkt-1(CA) cells were approximately 4.3-fold more resistant to the effects of 4HT than MCF-7 cells, implicating the importance of AKT expression on the efficacy of tamoxifen in breast cancer.

Activation of the PI3K/AKT/mTOR pathway has also been implicated in the resistance to aromatase inhibitors in breast cancer lines. In one study, the molecular mechanisms involved letrozole-resistant (LR) cell clones from ER+ aromatase-expressing breast cancer cell lines, MCF-7/AROM-1\[^{[24]}\]. In the LR cell line, there was an upregulation of the PI3K/AKT/mTOR pathway, indicated by increased phosphorylation of AKT1/mTOR and their downstream substrates, and an increase in Erα protein expression in these cells. In the same study, as a proof of concept in vitro, nine patients receiving letrozole alone in a neo-adjuvant setting for six months, developed an early increase of tumor mass in 3 months after an initial response to the drug. This was evidenced by breast ultrasound and Ki67 expression; the latter was done at baseline, after 14 days as a marker for early response, and at tumor progression. Paired tumor sections from both pre-treatment and post-treatment showed that there was significant upregulation of the PI3KCA, AKT1, and mTOR genes and their corresponding protein levels.

ANTICANCER EFFECTS OF STATINS

Multiple studies have demonstrated the role of statins in overcoming endocrine resistance [Table 1]. Simvastatin (SVA) is a lipophilic statin derived from lovastatin and has been found to mitigate endocrine resistance by a variety of mechanisms. Tamoxifen resistance, specifically, has been associated with the activation of retinoblastoma protein (Rb), an integral regulator of G1/S-phase cell-cycle progression. Deregulation of this pathway is associated with early recurrence of breast cancer following tamoxifen monotherapy\[^{[25]}\]. Additionally, minichromosome maintenance protein 7 (MCM7) is a part of a larger MCM complex and another key regulator of the cell cycle\[^{[26]}\]. Knockdown of MCM7 leads to abnormal replication of DNA during the S phase, which in turn activates the DNA damage response in order to halt cell-cycle

<table>
<thead>
<tr>
<th>Study</th>
<th>Statin studied</th>
<th>Lipophilic vs. hydrophilic</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liang et al.[^{[28]}]</td>
<td>Simvastatin + Tamoxifen</td>
<td>Lipophilic</td>
<td>Downregulates expression of MCM7 leading to DNA damage in tamoxifen-resistant cells</td>
</tr>
<tr>
<td>Liu et al.[^{[31]}]</td>
<td>Tamoxifen + Simvastatin</td>
<td>Lipophilic</td>
<td>Reduces isoprenoid intermediates of the mevalonate pathway</td>
</tr>
<tr>
<td>Moriai et al.[^{[32]}]</td>
<td>Lovastatin + Tamoxifen</td>
<td>Lipophilic</td>
<td>Inhibits ERK1/2 pathway, which leads to activation of SASP</td>
</tr>
<tr>
<td>Kusama et al.[^{[38]}]</td>
<td>Fluvastatin</td>
<td>Lipophilic</td>
<td>Inhibition of Rho A and Rho C membrane localization, thereby impairing cancer cell migration and invasion into the endothelial cell layer</td>
</tr>
<tr>
<td>Liu et al.[^{[39]}]</td>
<td>Fatostatin + Tamoxifen</td>
<td>-</td>
<td>Inhibitors of SREBP pathway resulting in decreased tumor cell invasion</td>
</tr>
<tr>
<td>Iizuka-Ohashi et al.[^{[42]}]</td>
<td>Fluvastatin</td>
<td>Lipophilic</td>
<td>Degradation of ER protein PI3K-AKT-mTOR signaling disruption leading to apoptosis and autophagy</td>
</tr>
<tr>
<td>Miettinen et al.[^{[44]}]</td>
<td>Atorvastatin</td>
<td>Lipophilic</td>
<td>Enhanced tamoxifen-induced apoptosis and autophagy</td>
</tr>
<tr>
<td>Shojaei et al.[^{[45]}]</td>
<td>Simvastatin + Temozolomide</td>
<td>Lipophilic</td>
<td>Inhibition of Rho A and Rho C membrane localization, thereby impairing cancer cell migration and invasion into the endothelial cell layer</td>
</tr>
<tr>
<td>Misirkic et al.[^{[46]}]</td>
<td>Simvastatin</td>
<td>Lipophilic</td>
<td>Upregulation of autophagosome-associated LC3-II indicating induction of autophagy</td>
</tr>
<tr>
<td>Toepfer et al.[^{[47]}]</td>
<td>Atorvastatin</td>
<td>Lipophilic</td>
<td>Upregulation of autophagosome-associated LC3-II indicating induction of autophagy</td>
</tr>
<tr>
<td>Qi et al.[^{[48]}]</td>
<td>Simvastatin</td>
<td>Lipophilic</td>
<td>Upregulation of autophagosome-associated LC3-II indicating induction of autophagy</td>
</tr>
</tbody>
</table>

Table 1. Mechanisms of statins in prevention of endocrine resistance and cancer recurrence
progression[27]. SVA has been shown to downregulate both Rb and MCM7 in two tamoxifen-resistant breast cancer cell lines, MCF7 and T47D, thereby leading to DNA damage. The addition of simvastatin to tamoxifen, however, demonstrates retarded growth of the tamoxifen-resistant cells leading to an induction of apoptosis[28]. Given that the increased prenylation signaling downstream of the cholesterol synthesis pathway that arguably contributes to endocrine resistance, the aforementioned data suggest that effective blockade of the mevalonate pathway may aid in re-sensitizing breast cancer cells.

Simvastatin can suppress breast cancer cell proliferation by affecting cellular senescence. Senescence represents the stress response of the cell to factors such as DNA damage and oncogene activation[29]. In response to these triggers, the cells acquire a senescence-associated secretory phenotype (SASP) that secretes different cytokines, growth factors, chemokines, and proteases, which promote inflammation and cancer progression[30]. In vitro, MCF7 breast cancer cells treated with fulvestrant exhibited lesser treatment effects upon co-culture with senescent vs. non-senescent cells[31], implicating senescence as a mechanism that leads to endocrine resistance. However, upon treatment of senescent cells with simvastatin, fulvestrant treatment effects were significantly enhanced, suggesting that simvastatin can mitigate the effects of senescent cells on endocrine resistance in breast cancer cells. A possible explanation for this effect involves an inhibitory effect on ERK1/2 pathway activation in SASP, which has been further linked with poor response to hormone therapy in breast cancer patients[32]. Rho GTPases, such as Rac1 and Cdc42, which control cell motility, adhesion, and proliferation are additionally dysregulated in SASP[33]. SV A appears to mitigate the effects of these key regulators that lead to SASP-induced endocrine resistance.

In a separate study, survivin was identified as a direct inhibitor of caspase-3 and caspase-7, causing a blunting of tamoxifen-induced apoptosis in MCF-7 and ZR-75-1 breast cancer cells[34,35]. This effect was diminished with lovastatin pre-treatment by the downregulation of survivin expression, thus increasing apoptosis.

Statins have also been shown to inhibit migration and invasion of breast cancer cells in vitro by preventing geranylgeranylation of Rho. The Rho family of proteins consists of GTPases including Rho A and Rho C that are overexpressed in breast cancer, and implicated in cancer cell migration and invasion[36]. To be fully functional, they require post-translational isoprenylation by specific transferases, farnesyltransferase, and geranylgeranyltransferase type I[37]. MDA-MB-231 cells previously treated with fluvastatin demonstrate decreased levels of Rho A and Rho C, which in turn leads to inhibition of transendothelial migration and invasion[38]. Cell invasion was further found to be impaired in MCF-7, T47D, MDA-MB-231, and MDA-MB-468 cells treated with both fatostatin and tamoxifen, owing to a synergistic effect between the agents and the ability of fatostatin to degrade ER via K-48 linked polyubiquitination. An added benefit of fatostatin in this study contributed to autophagy and apoptosis[39].

Statins may have a role in overcoming resistance to MEK inhibitors such as tramatenib and CH5126766. In a preclinical study, several cancer cell lines including the human breast cancer cells, MDA-MB-231, were treated with a MEK inhibitor, CH5126766, with or without statins[40]. There was a dose-dependent reduction in cell growth in cancer cells treated with combined CH5126766 and fluvastatin versus CH5126766 alone. Flow cytometric analysis of the cell cycle demonstrated that treatment with statins induced G1 arrest in MDA-MB-231 cells irrespective of CH5126766 administration. Activation of PI3K-AKT signaling and the subsequent increased expression of SREBPs following inhibition of the MEK pathway plays a role in the apoptotic resistance of cancer cells to MEK inhibitors. The addition of fluvastatin or simvastatin was able to suppress CH5126766-induced activation of AKT. Therefore, the utilization of statins in the blockade of the mevalonate pathway leads to the suppression of AKT activation and a decreased apoptotic resistance to MEK inhibitors.
AUTOPHAGY AND STATINS

Autophagy is a recycling pro-survival process where cells breakdown the utilized cytoplasmic products, which are then incorporated as auto-phagolysosomes and converted into inputs of cell metabolism\(^{[41]}\). Induction of autophagy is associated with the development of therapeutic resistance in breast cancer\(^{[42]}\). In fact, previous research shows that tamoxifen induces protective autophagy and the eventual induction of endocrine resistance in breast cancer cells, which can become re-sensitized by inhibiting autophagy\(^{[42-43]}\).

Autophagy is regulated by the mevalonate pathway in the form of geranylgeranylation of small Rab GTPases. Particularly, Rab11 has been proposed as the main link between the mevalonate pathway and autophagy. Inhibition of the mevalonate pathway with atorvastatin induces accumulation of autophagosomes and reduced autophagic flux\(^{[44]}\). Conversely, other studies have suggested that statin use does not block autophagic flux by blocking the mevalonate pathway, but rather interferes in phagolysosome formation\(^{[45]}\). Use of simvastatin in combination with temozolomide showed statin-induced accumulation of autophagosomes and enhanced proapoptotic cell death by temozolomide. It is important to note that the opposite has also been reported, suggesting that high dose statins could in fact increase autophagic flux, as measured by LC3II\(^{[46,47]}\). However, an increase in LC3II levels and autophagosomes can be seen upon inhibition of autophagic flux\(^{[47]}\). Simvastatin has also been shown to induce cytoplasmic accumulation of autophagic vacuoles, which was reversed by the addition of farnesyl and GGPP in a model of amyotrophic lateral sclerosis\(^{[48]}\).

STATIN USE AND OUTCOMES IN CLINICAL TRIALS

In a clinical study examining postmenopausal women with early HR+ breast cancer receiving adjuvant AI therapy, breast cancer recurrence over a 5-year follow-up period was significantly less in patients concomitantly exposed to a statin\(^{[49]}\). The incidence rate per 1000 person-years was 10.12 (95%CI: 6.92-14.28) in statin-exposed patients and 13.40 (95%CI: 12.36-14.51) in the non-exposed group. Any statin exposure was associated with a reduced rate of 5-year breast cancer recurrence [adjusted HR 0.72 (95%CI: 0.50-1.04)]. In the metastatic setting, an open-labelled phase II clinical study is currently recruiting and will evaluate the benefit of atorvastatin addition to standard endocrine therapy in the second line setting (NCT02958852). While in vitro and in vitro data support an integral role for the mevalonate pathway in the development of resistance to endocrine therapies, larger scale analyses of clinical data are needed to guide the use of lipid metabolism modulators in clinical practice.

CONCLUSION

Our review demonstrates the potential role of statins in overcoming endocrine resistance, an inevitable challenge in the treatment of HR+ breast cancer. There are several reasons that make statins a practical choice in the treatment of breast cancer. They are commonly prescribed medications used primarily for the management of hyperlipidemia and cardiovascular disease. According to a report by the Center for Disease Control and Prevention, 23.6% and 38.9% of women over 45 or 75 years, respectively were taking statins\(^{[50]}\). In addition, because of their widespread popularity in the prevention of both primary and secondary cardiovascular diseases, generic statin medications now cost < $12/month\(^{[51]}\). Statins are also generally well tolerated medications, although it is important to acknowledge their limiting side effects including myopathy that precludes its use in a subpopulation of patients. Also, metabolic syndrome and obesity together are linked with nearly 20% of breast cancers, particularly in the post-menopausal setting\(^{[52]}\). Treating obesity and associated comorbidities such as hypercholesterolemia has shown to prevent more than 30% of breast cancers. All these factors make statins a logical choice and should prompt clinical trials to further investigate the role of statins in endocrine-resistant breast cancer.
DECLARATIONS

Author's contributions
Conceptualized, wrote, and edited the manuscript: Hyder T, Marti JLG, Nasrazadani A, Brufsky AM

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES


